Inhibition of GH release in rats by new potent antagonists of growth hormone-releasing hormone (GH-RH)

Peptides

Volumn 18, Issue 3, 1997, Pages 431-438

  Kovács, Magdolna ^a,b   Schally, Andrew V ^a,c   Zarándi, Márta ^a,d   Groot, Kate ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PÉCS   (Hungary)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF SZEGED   (Hungary)

Author keywords

GH release; GH RH antagonist; Inhibitory potency; Routes of administration

Indexed keywords

GROWTH HORMONE RELEASING FACTOR; GROWTH HORMONE RELEASING FACTOR ANTAGONIST; MZ 5 156; SOMATOMEDIN; UNCLASSIFIED DRUG;

ACROMEGALY; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DIABETIC RETINOPATHY; DOSE RESPONSE; DRUG MECHANISM; DRUG POTENCY; GROWTH HORMONE RELEASE; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG CARCINOMA; MALE; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; CELLS, CULTURED; GROWTH HORMONE; GROWTH HORMONE-RELEASING HORMONE; INJECTIONS, INTRAMUSCULAR; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MALE; PERFUSION; PITUITARY GLAND; RATS; RATS, SPRAGUE-DAWLEY; SERMORELIN;

ANIMALIA;

EID: 0030908486     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0196-9781(96)00334-8     Document Type: Article

References (30)

1. Angelloz-Nicoud P., Binoux M. Autocrine regulation of cell proliferation by the insulin-like growth factor (IGF) and IGF binding protein-3 protease system in a human prostate carcinoma cell line (PC-3). Endocrinology. 136:1995;5485-5492.
2. Bergmann U., Funatomi H., Yokoyama M., Beger H. G., Korc M. Insulin-like growth factor-I overexpression in human pancreatic cancer: Evidence for autocrine and paracrine roles. Cancer Res. 55:1995;2007-2011.
3. Coy D. H., Hocart S. J., Murphy W. A. Human growth hormone-releasing hormone analogues with much improved in vitro growth hormone-releasing potencies in rat pituitary cells. Eur. J. Pharmacol. 204:1991;179-185.
4. Csernus V. J., Schally A. V. The dispersed cell superfusion system. Greenstein B. D. Neuroendocrine research methods. 1991;71-109 Harwood Academic Publishers, London.
5. Daughaday W. H. Editorial: The possible autocrine/paracrine and endocrine roles of insulin-like growth factors of human tumors. Endocrinology. 127:1990;1-4.
6. Frohman L. A., Downs T. R., Heimer E. P., Felix A. M. Dipeptidylpeptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma. J. Clin. Invest. 83:1989;1533-1540.
7. Hanew K., Tanaka A., Utsumi A., Sugawara A., Abe K. Plasma GH responses to human GHRH-antagonist in normal subjects. Eur. J. Endocrinol. 134:1996;67-72.
8. Hocart S. J., Murphy W. A., Coy D. H. Analogues of growth hormone-releasing factor (1-29) amide containing the reduced peptide bond isostere in the N-terminal region. J. Med. Chem. 33:1990;1954-1958.
9. Jaffe C. A., DeMott Frieberg R., Barkan A. L. Suppression of growth hormone (GH) secretion by a selective GH-releasing hormone (GHRH) antagonist. J. Clin. Invest. 92:1993;695-701.
10. Kovács M., Zarándi M., Halmos G., Groot K., Schally A. V. Effects of acute and chronic administration of a new potent antagonist of growth hormone-releasing hormone in rats: Mechanisms of action. Endocrinology. 137:1996;5364-5369.
11. Ling N., Sato K., Hotta M., Chiang T.-C., Hu H.-Y., Dong M.-H. Growth hormone-releasing factor analogs with potent antagonist activity. Marshall G. R. Peptides: Chemistry and biology. 1988;484-486 ESCOM, Leiden.
12. Lumpkin M. D., Mulroney S. E., Haramati A. Inhibition of pulsatile growth hormone (GH) secretion and somatic growth in immature rats with a synthetic GH-releasing factor antagonist. Endocrinology. 124:1989;1154-1159.
13. Lumpkin M. D., McDonald J. K. Blockade of growth hormone-releasing factor (GRF) activity in the pituitary and hypothalamus of the conscious rat with a peptidic GRF antagonist. Endocrinology. 124:1989;1522-1531.
14. Macaulay V. M. Insulin-like growth factors and cancer. Br. J. Cancer. 65:1992;311-320.
15. Pinski J., Schally A. V., Groot K., Halmos G., Szepesházi K., Zarándi M., Armatis P. Inhibition of growth of human osteosarcomas by antagonists of growth hormone-releasing hormone. J. Natl. Cancer Inst. 87:1995;1787-1794.
16. Pinski J., Schally A. V., Jungwirth A., Groot K., Halmos G., Armatis P., Zarándi M., Vadillo-Buenfil M. Inhibition of growth of human small-cell and nonsmall-cell lung carcinomas by antagonists of growth hormone-releasing hormone (GH-RH). Int. J. Oncol. 9:1996;1099-1105.
17. Pollak M. N., Richard M. J. Suramin blockade of insulinlike growth factor I-stimulated proliferation of human osteosarcoma cells. J. Natl. Cancer Inst. 82:1990;1349-1352.
18. Pollak M. N., Polychronakos C., Richard M. Insulinlike growth factor I: A potent mitogen for human osteogenic sarcoma. J. Natl. Cancer Inst. 82:1990;301-305.
19. Rékási Z., Schally A. V. A method for evaluation of activity of antagonistic analogs of growth hormone-releasing hormone in a superfusion system. Proc. Natl. Acad. Sci. USA. 90:1993;2146-2149.
20. 2 as a GRF antagonist on membranes. Endocrinology. 117:1985;1759-1764.
21. Sato K., Hotta M., Kageyama J., Chiang T.-C., Hu H.-Y., Dong M.-H., Ling N. Synthesis and in vitro bioactivity of human growth hormone-releasing factor analogs substituted with a single D-amino acid. Biochem. Biophys. Res. Commun. 149:1987;531-537.
22. Sato K., Hotta M., Kageyama J., Hu H.-Y., Dong M.-H., Ling N. Synthetic analogs of growth hormone-releasing factor with antagonistic activity in vitro. Biochem. Biophys. Res. Commun. 167:1990;360-366.
23. Schally A. V. Oncological applications of somatostatin analogs. Cancer Res. 48:1988;6977-6985.
24. Schally A. V., Comaru-Schally A. M. Hypothalamic and other peptide hormones. Holland J. F., Frei E. III, Bast R. C. Jr., Kufe D. E., Morton D. L., Weichselbuam R. R. Cancer medicine. 4th ed. 1997;1067-1068 Williams and Wilkins Publishers, Baltimore, MD.
25. Toretsky J. A., Helman L. J. Involvement of IGF-II in human cancer. J. Endocrinol. 149:1996;367-372.
26. Vigh S., Schally A. V. Interaction between hypothalamic peptides in a superfused pituitary cell system. Peptides. 5:1984;241-247.
27. Westley B. R., May F. E. B. Insulin-like growth factors: The unrecognised oncogenes. Br. J. Cancer. 72:1995;1065-1066.
28. Wheeler M. D., Wehrenberg W. W., Stune D. M. Growth hormone regulation by growth hormone-releasing hormone in infant rhesus monkeys. Biol. Neonate. 60:1991;19-28.
29. Zarándi M., Horváth J. E., Halmos G., Pinski J., Nagy A., Groot K., Rékási Z., Schally A. V. Synthesis and biological activities of highly potent antagonists of growth hormone-releasing hormone. Proc. Natl. Acad. Sci. USA. 91:1994;1298-12301.
30. Zarándi, M.; Kovács, M.; Horváth, J. E.; Tóth, K.; Halmos, G.; Groot, K.; Nagy, A.; Schally, A. V. Synthesis and in vitro evaluation of new potent antagonists of growth hormone-releasing hormone (GH-RH). Peptides (in press).